|Day Low/High||3.83 / 3.96|
|52 Wk Low/High||2.15 / 5.78|
Xoma's promising study results on a diabetes drug makes it more likely it will find a partner.
Shares of the biopharmaceutical company slid after it posted a widened quarterly loss and slashed staff.
Shares jump 228.5% on a report that Bristol-Myers Squibb will buy the company.
Vivus climbs on interim data for a midstage study on obesity drug Qnexa.
Dendreon's still dizzying, and other stock news from the biotech world.
An agency staff report raises questions about the company's female hormone drug Intrinsa.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.